Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupropion controlled-release - IntelGenx

Next Previous
X
Search
Drug Profile

Bupropion controlled-release - IntelGenx

Alternative Names: Bupropion extended-release; CPI-300; Forfivo XL; INT 0004/2006

Latest Information Update: 02 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cary Pharmaceuticals; IntelGenx Corp.
  • Developer IntelGenx Corp.
  • Class Antidepressants; Obesity therapies; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Major depressive disorder

Highest Development Phases

  • Marketed Major depressive disorder

Most Recent Events

  • 02 Dec 2014 IntelGenx extends license agreement with Edgemont Pharmaceuticals for the commercialisation of bupropion controlled-release in USA
  • 27 Nov 2014 Bupropion controlled-release - IntelGenx is available for licensing in (excluding USA) as of 27 Nov 2014. http://www.intelgenx.com
  • 28 Aug 2013 Wockhardt Bio AG advises IntelGenx of an ANDA submission to manufacture and market generic versions of Fortivo® XL 450mg capsules in the US

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top